Company intelligence / Profile preview

Lasergen

Houston, Texas, United States

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Lasergen developed a novel DNA sequencing chemistry (“Lightning Terminators”) integrated into next-generation sequencing workflows for clinical genomics, with demonstrated potential for faster, more accurate, and cost-effective sequencing; acquired by Agilent for further commercial development in molecular diagnostics.

Modalities: DNA sequencing chemistryNot therapeutic: Lasergen does not develop drugs, but develops DNA sequencing platform chemistry (not a therapy—technology for genomics)
Industry: Molecular Diagnostics

Partnerships

Agilent Technologies (deep partnership for NGS workflow, culminated in acquisition)

Beyond the preview

Go deeper on Lasergen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lasergen.

Explore the full profile